Clinical Trials Sponsored by Sihuan Pharmaceutical Holdings Group Ltd.

Total 684 results

Shanghai Pharmaceuticals Holding Co., Ltd

Recruiting

A Clinical Study of T3011 in Subjects With Advanced Melanoma

Advanced Melanoma

China
Shanghai Pharmaceuticals Holding Co., Ltd

Recruiting

A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors.

Advanced Solid Tumors

China
Shanghai Pharmaceuticals Holding Co., Ltd

Recruiting

Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.

Breast Cancer Brain Metastases

China
Shanghai Pharmaceuticals Holding Co., Ltd

Recruiting

Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer

Locally Advanced or Metastatic Breast Cancer

China
Shanghai Pharmaceuticals Holding Co., Ltd

Recruiting

A Study of SPH3127 in the Treatment of Mild to Moderate Ulcerative Colitis

Mild to Moderate Ulcerative Colitis

China
Shanghai Pharmaceuticals Holding Co., Ltd

Recruiting

Efficacy and Safety of LT3001 on Treating the Acute Ischemic Stroke

Acute Ischemic Stroke

China
Shanghai Pharmaceuticals Holding Co., Ltd

Recruiting

Efficacy and Safety of SPH3127 Tablets on Treating the Diabetic Kidney Disease

Diabetic Kidney Disease

China
Shanghai Pharmaceuticals Holding Co., Ltd

Recruiting

SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors

HER2-positive Advanced Solid Tumors

China
Shanghai Pharmaceuticals Holding Co., Ltd

Recruiting

A Clinical Study of TK216 in Patients With Relapsed or Refractory Ewing's Sarcoma

Sarcoma, Ewing

China
Shanghai Pharmaceuticals Holding Co., Ltd

Completed

A Food Effect Study of SPH5030 Tablets.

Advanced Solid Tumor

China
Shanghai Pharmaceuticals Holding Co., Ltd

Completed

B002 in Patients With HER2-positive Breast Cancer (B002-101)

Metastatic Breast Cancer | Recurrent Breast Cancer

China
Shanghai Pharmaceuticals Holding Co., Ltd

Completed

Study on Human Mass Balance of SPH3127 Tablets

Primary Mild and Moderate Hypertension

China
Shanghai Pharmaceuticals Holding Co., Ltd

Completed

Single Ascending Dose Study of Safety and Tolerability of SPH3127 Tablet in Chinese Healthy Volunteers

Hypertension

China
Shanghai Pharmaceuticals Holding Co., Ltd

Completed

The Tolerability and Pharmacokinetics of Multiple Doses of SPH3127 in Chinese Healthy People

Hypertension

China
Shanghai Pharmaceuticals Holding Co., Ltd

Completed

The Effect of Food Intake on the Pharmacokinetic of Single Dose SPH3127 Tablets in Chinese Health Subjects

Hypertension

China
Shanghai Pharmaceuticals Holding Co., Ltd

Completed

Hydroxytriptolide in Active Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate (T8)

Rheumatoid Arthritis

China
Shanghai Pharmaceuticals Holding Co., Ltd

Recruiting

A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors

Advanced Solid Tumors

China
Shanghai Pharmaceuticals Holding Co., Ltd

Recruiting

Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer

Locally Advanced or Metastatic Breast Cancer

China
Shanghai Pharmaceuticals Holding Co., Ltd

Recruiting

Clinical Study of SPH3348 Tablets, a c-Met Inhibitor, in Patients With Advanced Solid Tumors

Solid Tumor

China
Shanghai Pharmaceuticals Holding Co., Ltd

Completed

Study to Evaluate the Efficacy and Safety of SPH3127 In Patients With Mild-moderate Essential Hypertension

Essential Hypertension

China
Shanghai Pharmaceuticals Holding Co., Ltd

Active, not recruiting

Phase I Clinical Study of SPH4336 Tablets in the Treatment of Advanced Solid Tumors

Advanced Solid Tumors

China
Shanghai Pharmaceuticals Holding Co., Ltd

Completed

Safety and Efficacy of T8 on Treating Chronic Abnormal Immune Activation in HIV/AIDS Patients

Chronic Abnormal Immune Activation in HIV/AIDS

China
Shanghai Pharmaceuticals Holding Co., Ltd

Completed

B001 in Patients With CD20 Positive B-cell Non Hodgkin's Lymphoma

CD20 Positive B Cell Non-Hodgkin's Lymphoma

China
Shanghai Pharmaceuticals Holding Co., Ltd

Withdrawn

Phase I Study of SPH1188-11 in NSCLC (SPH1188-11)

NSCLC Stage IV | NSCLC Stage IIIB

China
Shanghai Pharmaceuticals Holding Co., Ltd

Completed

Phase II Clinical Study of Thalidomide in the Treatment of Ankylosing Spondylitis

Ankylosing Spondylitis

China
Shanghai Pharmaceuticals Holding Co., Ltd

Recruiting

Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD)

NMO Spectrum Disorder

China
Shanghai Pharmaceuticals Holding Co., Ltd

Completed

A Clinical Study of SPH6516 Tablets in the Treatment of Advanced Solid Tumors.

Advanced Solid Tumor

China
Shanghai Pharmaceuticals Holding Co., Ltd

Completed

B003 in Patients With HER2-positive Recurrent or Metastatic Breast Cancer (B003-101)

HER2-positive Breast Cancer

China
Shanghai Pharmaceuticals Holding Co., Ltd

Completed

Drug-drug Interaction Study of SPH3127

Drug Drug Interaction

China
Foresee Pharmaceuticals Co., Ltd.
QPS Holdings LLC; Changchun GeneScience Pharmaceutical Co., Ltd.

Recruiting

Efficacy, Safety, and Pharmacokinetics of Leuprolide Mesylate in Subjects With Central Precocious Puberty

Puberty; Precocious, Central

United States, China, Taiwan, Puerto Rico
Sichuan University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Anlotinib Hydrochloride Combined With AP in Stage IIIB/IIIC/IV Non-squamous Non-small-cell Lung Cancer

Non-squamous Non-small-cell Lung Cancer | Anlotinib

China
Sichuan Honghe Biotechnology Co., Ltd.

Recruiting

Phase 1 Trial of KH617

Advanced Solid Tumors

China
Sichuan Haisco Pharmaceutical Group Co., Ltd
The First Hospital of Jilin University

Completed

Safety and Pharmacokinetics/Pharmacodynamics of HSK3486 in Patients With Hepatic Impairment

Hepatic Impairment

China
Pfizer
Biohaven Pharmaceutical Holding Company Ltd.

Recruiting

Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects

Migraine

United States, France, Spain, Poland, Japan, Canada, Italy
Pfizer
Biohaven Pharmaceutical Holding Company Ltd.

Active, not recruiting

Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens

Migraine

Spain, United States, France, Canada, Germany, United Kingdom, Poland, Austria, Sweden, Italy
Pfizer
Biohaven Pharmaceutical Holding Company Ltd.

Completed

Safety and Efficacy of BHV-3000 (Rimegepant) Orally Disintegrating Tablet for the Acute Treatment of Chronic Rhinosinusitis

Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps

United States
Pfizer
Biohaven Pharmaceutical Holding Company Ltd.

Terminated

Safety and Efficacy of BHV-3000 (Rimegepant) Orally Disintegrating Tablet for Acute Treatment of Temporomandibular Disorders

Temporomandibular Disorders (TMD)

United States
Sichuan Haisco Pharmaceutical Group Co., Ltd
The First Hospital of Jilin University

Completed

Safety and Pharmacokinetics/Pharmacodynamics of HSK3486 in Healthy Elderly Subjects

Healthy Elderly Subjects

China
Sichuan Baili Pharmaceutical Co., Ltd.

Recruiting

A Study of SI-B003 or BL-B01D1+SI-B003 in Patients With Unresectable Locally Advanced or Recurrent Metastatic HER2 Negative Breast Cancer

Breast Cancer

China
Sichuan Baili Pharmaceutical Co., Ltd.

Recruiting

A Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Sichuan Baili Pharmaceutical Co., Ltd.

Recruiting

A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

China
Sichuan Baili Pharmaceutical Co., Ltd.

Recruiting

A Study of BL-B01D1 Combined With Osimertinib Mesylate Tablets in Patients With Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Sichuan Baili Pharmaceutical Co., Ltd.

Recruiting

A Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in the Treatment of Recurrent and Metastatic HNSCC

Head and Neck Squamous Cell Carcinoma

China
Sichuan Huiyu Pharmaceutical Co., Ltd

Recruiting

Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS Mutation

Efficacy | Tolerability | Safety

China
Sichuan Baili Pharmaceutical Co., Ltd.

Recruiting

A Study of BL-M07D1 in Patients With HER2-mutated, Locally Advanced or Metastatic Non-small-cell Lung Cancer

Non-small Cell Lung Cancer

China
Sichuan Baili Pharmaceutical Co., Ltd.

Recruiting

A Study of BL-M07D1 in Patients With a Variety of Solid Tumors Including Locally Advanced or Metastatic HER2-positive/Low-expressing Urinary and Gastrointestinal Tumors

Her2-positive/Low-expression Urinary and Digestive Tract Tumors

China
Sichuan Baili Pharmaceutical Co., Ltd.

Recruiting

A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (Non-nasopharyngeal Carcinoma) and Other Solid Tumors

Head and Neck Squamous Cell Carcinoma

China
Sichuan Baili Pharmaceutical Co., Ltd.

Recruiting

A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors

Non-small Cell Lung Cancer

China
Sichuan Baili Pharmaceutical Co., Ltd.

Recruiting

A Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological Malignancies

Relapsed/Refractory Chronic Lymphocytic Leukemia

China
Sichuan Baili Pharmaceutical Co., Ltd.

Recruiting

A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma

Squamous Cell Carcinoma of Lung | Non-small Cell Lung Adenocarcinoma

China

Clinical Trials Sponsored by Sihuan Pharmaceutical Holdings Group Ltd.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uruguay

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations